Basis of radiopharmaceutical localization

The Pathophysiologic Basis of Nuclear Medicine

Volumn , Issue , 2015, Pages 45-68

  Vallabhajosula, Shankar ^a   Owunwanne, Azu ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944556543     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-06112-2_3     Document Type: Chapter

References (95)

1. Wagner HN Jr (1995) The diagnostic process. In:Wagner HN Jr, Szabo Z, Buchanan JW (eds)Principles of nuclear medicine. WB Saunders,Philadelphia, pp 9-17
2. Wagner HN Jr (1995) Nuclear medicine: what it isand what it does. In: Wagner HN Jr, Szabo Z, Buchanan JW (eds) Principles of nuclear medicine. WB Saunders, Philadelphia, pp 1-8
3. Krasnow AZ, Heilman RS, Timins ME et al (1997)Diagnostic bone scanning in oncology. Semin NuclMed 27:107-141
4. Grynpas MD (1990) Fluoride effects on bone crystal.J Bone Miner Res 5(Suppl 1):5169-5175
5. Owunwanne A, Halkar RA, Abubaker KC et al (1988)Radionuclide imaging of the spleen with heat denatured 99mTc-RBC when splenic reticuloendothelialsystem seems impaired. J Nucl Med 29:320-323
6. Adekile AD, Owunwanne A, Al-Za’abi K et al (2002)Temporal sequence of splenic dysfunction in sicklecell disease. Am J Hematol 69:23-27
7. Delmon-Moingeon LI, Piwinca-Wormas D,Van den Abbeele AD, Holman BL, Davison A,Jones AG (1990) Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m byhuman carcinoma cell lines in vitro. Cancer Res50:2198-2202
8. Piwnica-Worms D, Kronauge JF, Chiu ML (1990)Uptake and retention of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured chick myocardialcells. Mitochondrial and plasma membrane potentialdependence. Circulation 82:1826-1838
9. Arbab AS, Koizumi K, Toyama K, Araki T (1996)Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J NuclMed 37:1551-1556
10. Piwnica-Worms D, Chiu ML, Budding M, KronaugeJF, Kramer R, Croop JM (1993) Functional imagingof multidrug-resistant P-glycoprotein with an organo-technetium complex. Cancer Res 53:977-984
11. Hendrikse NH et al (1998) 99mTc-sestamibi is a substrate for P-glycoprotein and the multi-drug resistanceassociated protein. Br J Cancer 77:353-358
12. Tsan MF, Scheffel U (1986) Mechanism of gallium-67 accumulation in tumors. J Nucl Med 27:1215-1219
13. Weiner RE (1996) The mechanism of 67 Ga localization in malignant disease. Nucl Med Biol 23:745-751
14. Vallabhajosula SR, Harwig JF, Siemsen JK et al(1980) Radiogallium localization in tumors: bloodbinding and transport and the role of transferrin. JNucl Med 21:650-656
15. Hayes RL, Rafter JJ, Byrd BL, Carlton JE (1981)Studies of the in vivo entry of Ga-67 into normal andmalignant tissue. J Nucl Med 22:325-332
16. Pauwels EK, Sturm EJ, Bombardieri E, Cleton FJ,Stokkel MP (2000) Positron-emission tomographywith [18F] fluorodeoxy glucose. Part 1. Biochemicaluptake mechanism and its implication for clinicalstudies. J Cancer Res Clin Oncol 126:549-559
17. Sviderskaya EV, Jazrawi E, Baldwin SA, Widnell CC,Pasternak CA (1996) Cellular stress causes accumulation of the glucose transporter at the surface of cellsindependently of their insulin sensitivity. J MembrBiol 149:133-140
18. Theorens B, Sarkar HK, Kaback HR, Lodish HF(1988) Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells. Cell 55:281-290
19. Maher F (1995) Immunolocalization of GLUT1 andGLUT3 glucose transports in primary cultured neurons and glia. J Neurosci Res 42:459-469
20. Rea S, James DE (1997) Moving GLUT4: the biogenesis and trafficking of GLUT4 storage vesicles.Diabetes 46:1667-1677
21. Gallagher BM, Fowler JS, Gutterson NI et al (1978)Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F]2-deoxy-2-fluoro-D-glucose. J NuclMed 19:1154-1161
22. Kubota R, Yamada S, Kubota K et al (1992)Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation inmacrophages and granulation tissues studied bymicroautoradiographic comparison with FDG. J NuclMed 33:1872-1980
23. Schwenk M (1980) Transport systems of isolatedhepatocytes: studies on the transport of biliary compounds. Arch Toxicol 44:113-126
24. Okuda H, Nunes R, Vallabhajosula S et al (1986)Studies of the hepatocellular uptake of the hepatobiliary scintiscanning agent 99mTc-DISIDA. J Hepatol3:251-259
25. Nunn AD, Loberg MD, Conley RA (1983) A structurerelationship approach leading to the development of99mTc mebrofenin: an improved cholescintigraphicagent. J Nucl Med 24:423-430
26. Hudges RE, Evans TC, Bradbyry JT et al (1955) Theaccumulation of radioactive iodine by human fetalthyroids. Clin Endocrinol Metab 15:661-667
27. Weich HF, Strauss HW, Pitt B (1977) The extractionof thallium-201 by the myocardium. Circulation56:188
28. Sessler M, Maul FD, Geck P, Munz D, Hor G (1982)Kinetics and mechanism of thallium uptake in malignant tumors in vivo and in vitro. In: Raynaud C (ed)3rd World Congress of Nuclear Medicine and Biology,August 29-September 2, Paris. Nucl Med Biol Proc1982:2281-2284
29. Sessler MJ, Geck P, Maul FD et al (1986) New aspectsof cellular Tl-201 uptake: co-transport is the centralmechanism of ion uptake. Nucl Med 25:24-27
30. Eshima D, Taylor A (1992) Tc-99m mercaptoacetyl-triglycine (Tc-99mMAG3): update on the newTc-99m renal tubular function agent. Semin NuclMed 22:61-73
31. Alazraki NP, Eshima D, Eshima LA et al (1997)Lymphoscintigraphy, the sentinel node concept, andthe intraoperative gamma probe in melanoma, breastcancer, and other potential cancers. Semin Nucl Med27:55-67
32. Mueckler M (1994) Facilitative glucose transporters.Eur J Biochem 219:713-725
33. Vaalburg W, Coenen HH, Crouzel C et al (1992)Amino acids for the measurement of protein synthesisin vivo by PET. Nucl Med Biol 19:227-237
34. Ishiwata K, Kubota K, Murakami M, Kubota R,Senda M (1993) A comparative study on proteinincorporation of L-[methyl-3H]methionine, L-[1-14C]leucine and L-[2-18F]fluorotyrosine in tumorbearing mice. Nucl Med Biol 20:895-899
35. Shoup TM, Olson J, Hoffman JM et al (1999)Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image braintumors. J Nucl Med 40:331-338
36. Wester HJ, Herz M, Weber W et al (1999) Synthesisand radiopharmacology of 0-[2-18F]fluorethyltyro-sine for tumor imaging. J Nucl Med 40:205-212
37. Linder K, Nunn A, Strauss HW (1995) Nitroimidazolesand imaging hypoxia. Eur J Nucl Med 22:265-280
38. Rasey JS, Koh WJ, Evans ML et al (1996) Quantifyingregional hypoxia in tumors with positron emissiontomography: a pretherapy study of 37 patients. Int JRadiat Oncol Biol Phys 36:417-428
39. Lewis JS, McCarthy DW, McCarthy TJ, FugibayashiY, Welch MJ (1999) Evaluation of 64Cu-ATSM invitro and in-vivo in a hypoxic tumor model. J NuclMed 40:177-183
40. Parliament MB, Chapman JD, Urtasunn RC et al(1992) Noninvasive assessment of human tumorhypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 65:90-95
41. Ballinger JR, Kee JWM, Rauth AM (1996) In vitroand in vivo evaluation of a technetium-99m-labeled2-nitroimidazole (BMS181321) as a marker of tumorhypoxia. J Nucl Med 37:1023-1031
42. Cook GJR, Houston S, Barrington SF, Fogelman I(1998) Technetium-99m-labeled HL91 to identifytumor hypoxia: correlation with fluorine-18-FDG.J Nucl Med 39:99-103
43. Warburg O (1956) On the origin of cancer cells.Science 123:309-314
44. Vallabhajosula SR, Harwig JF, Wolf W (1982) Effectof pH on tumor cell uptake of radiogallium in vitroand in vivo. Eur J Nucl Med 7:462-468
45. Livingston RB, Ambus U, George SL, Freireich EJ,Hart JS (1974) In vitro determination of thymidine-[3H] labeling index in human solid tumors. CancerRes 34:1376-1380
46. Goethals P, Lameire N, van Eijkeren M et al (1996)Methylcarbon-11 thymidine for in vivo measurementof cell proliferation. J Nucl Med 37:1048-1052
47. Kassis AI, Adelstein SJ (1996) Preclinical animalstudies with radioiododeoxyuridine. J Nucl Med37(Suppl):10s-12s
48. O’Donoghue JA (1996) Strategies for selective targetingof Auger electron emitters to tumor cells. J Nucl Med37(Suppl):3s-6s
49. Been LB, Suurmeijer AJH, Cobben DCP et al (2004)[18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 31:1659-1672
50. Reubi JC, Laissue J, Kenning EP, Lamberts SWJ(1992) Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinicalimplication. J Steroid Biochem Mol Biol 43:27-35
51. Patel YC, Greenwood MT, Panetta R, Demchyshyn L,Niznik H, Srikant CB (1995) Mini review: the somatostatin receptor family. Life Sci 57:1249-1265
52. Krenning EP, Kwekkeboom DJ, Bakker H et al (1993)Somatostatin receptor scintigraphy with[111 In-DTPA-D-Phe 1]- and [123I-Tyr3]-octreotide:the Rotterdam experience with more than 1000patients. Eur J Nucl Med 20:716-731
53. Virgolini I, Pangerl T, Bischof C, Smith-Jones P,Peck-Radosavljevic M (1997) Somatostatin receptorsubtype expression in human tissues: a prediction fordiagnosis and treatment of cancer? Eur J Clin Invest27:645-647
54. Lebtahi R, Le-Cloriec J, Houzard C et al (2002)Detection of neuroendocrine tumors: 99mTc-PS829scintigraphy compared with 111In-pentreotidescintigraphy. J Nucl Med 43:889-895
55. Hubalewska-Dydejczyk A, Fross-Baron K,Mikolajczak R et al (2006) 99mTcEDDA/HYNC-octreotate scintigraphy an efficient method for detection and staging of carcinoid tumours: results of3 years experience. Eur J Nucl Med Mol Imaging33:1123-1130
56. Cwika JB, Mikolajczak R, Pawlak D (2008) Initialdirect comparison of 99mTc-TOC and 99mTc-TATEin identifying sites of disease in patient withproven GEPNET. J Nucl Med 49:1060-1065
57. Ambrosin V, Melporneni F, Stelano F et al (2011)Radiopeptide imaging and therapy in Europe. J NuclMed 52(Suppl 2):42S-55S
58. de Jong M, Bakker WH, Krenning EP, Breeman WA,van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Behe M, Powell P, Macke HR (1997) 90Y and111In labeling, receptor binding and biodistributionof DOTA0, D-Phe1, Tyr3]octreotide, a promisingsomatostatin analog for radionuclide therapy. Eur JNucl Med 24:368-371
59. Stolz B, Weckbecker G, Smith-Jones PM, Albert Ret al (1998) The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-Dphe1-Tyr3]-Octreotide(SMT487) eradicates experimental rat pancreatic CA20948 tumors. Eur J Nucl Med 25:668-674
60. Virgolini I, Szilvasi I, Kurtaran A et al (1998) Indium-111-DOTA-lanreotide: biodistribution, safety andtumor dose in patients evaluated for somatostatin receptor-mediated radiotherapy. J Nucl Med 39:1928-1936
61. Kunikowska J, Krolick L, Hubalewska-Dydejczyk Aet al (2011) Clinical results of radionuclide therapy ofneuroendocrine tumors with 90Y-DOTA-TATE andtandem90Y/177Lu-DOTA-TATE: which is a bettertherapy option? Eur J Nucl Med Mol Imaging38:1788-1797
62. de Jong M, Breeman WA, Valkema R et al (2005)Combination radionuclide therapy using 177Lu and90Y-labeled somatostatin analogs. J Nucl Med46(Suppl 1):13S-17S
63. Bodei L, Cremonesi M, Grana CM et al (2011)Peptide receptor radionuclide therapy with177LuDOTATATE: the IEO phase I-II study. Eur JNucl Med Mol Imaging 38:2125-2155
64. Felce A, Fraternali A, Frasoldati A et al (2012)Radiolabeled somatostatin analogues therapy inadvanced neuroendocrine tumors: a single centerexperience. J Oncol 2012:320198
65. Oberg K (2012) Molecular imaging radiotherapy: ther-anostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2:448-458
66. Baum RP, Virgolini I, Ambrosin V et al (2010) Procedure guidelines for PET/CT tumor imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga_DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004-2010
67. Kwekkeboom DJ, Kam BL, van Essen M et al (2010)Somatostatin receptor-base imaging and therapy.Endocr Relat Cancer 17:R53-R73
68. Reubi JC (1995) In vitro identification of vasoactiveintestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 36:1846-1853
69. Virgolini I, Raderer M, Kurtaran A et al (1994)Vasoactive intestinal peptide-receptor imaging for thelocalization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331:1116-1121
70. Virgolini I, Yang Q, Li S et al (1994) Crosscompetition between vasoactive intestinal peptide andsomatostatin for binding to tumor cell membranereceptors. Cancer Res 54:690-700
71. Katzenellenbogen JA (1995) Designing steroid receptor based radiotracers to image breast and prostatetumors. J Nucl Med 36(Suppl):8s-13s
72. Rijks LJM, Boer GJ, Endert E et al (1996) The stereoisomers of 17alpha-[123I]iodovinyloestradiol and its11beta-methoxy derivative evaluated for their estrogen receptor binding in human MCF-7 cells and ratuterus, and their distribution in immature rats. Eur JNucl Med 23:295-307
73. Wieland DM, Swanson DP, Brown LE, BeierwaltersWH (1979) Imaging the adrenal medulla with anI-131-labeled anti-adrenergic agent. J Nucl Med20:155-158
74. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, WielandDM (1984) Comparison of sodium dependency ofuptake of metaiodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. MolPharmacol 26:539-546
75. Beierwalters WH, Weiland DM, Yu T, Swanson D,Mosley S (1978) Adrenal imaging agents. Rationale,synthesis, formulation and metabolism. Semin NuclMed 8:5-21
76. Kaminski MS, Zasadny KR, Francis IR et al (1993)Radioimmunotherapy of B-cell lymphoma with[131I]anti-B1 (anti-CD20) antibody. N Engl J Med329:459-465
77. Goedemans WT, Panek KJ, Ensing GJ et al (1990) Anew simple method for labeling of proteins with Tc-99m1-imino-4-mercaptobutyl groups. In: Nicolini M,Bandolini G, Mazzi U (eds) Technetium and rhenium inchemistry and nuclear medicine, vol 3. Raven Press/Cortina International, New York/Verona, pp 595-604
78. Joiris E, Bastin B, Thornback JR (1990) A new methodfor labeling of monoclonal antibodies, fragments and other proteins with technetium-99m. In: Nicolini M, Bandolini G, Mazzi U (eds) Technetium and rheniumin chemistry and nuclear medicine, vol 3. CortinaInternational/Raven Press, Verona/New York, pp609-614
79. Fritzberg AR, Abrams PG, Beaunier PC et al (1988)Specific and stable labeling of antibodies withtechnetium-99m with a diamide dithiolate chelatingagent. Proc Natl Acad Sci U S A 85:4025-4029
80. Knox S, Goris M, Trisler K et al (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy ofrecurrent B-cell lymphoma. Clin Cancer Res2:457-470
81. Stoldt HS, Aftab F, Chinol M et al (1997) Pretargetingstrategies for radioimmunoguided tumor localizationand therapy. Eur J Cancer 33:186-192
82. Hnatowich DJ, Virzi F, Rusckowski M (1987)Investigations of avidin and biotin for imaging applications. J Nucl Med 28:1294-1302
83. Paganelli G, Magnani P, Zito F et al (1991) Three-stepmonoclonal antibody tumor targeting in carcinoem-bryonic antigen-positive patients. Cancer Res51:5960-5966
84. Younes CK, Boisgard R, Tavitian B (2002) Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Des 8:1451-1466
85. Zhang YR, Zhang YX, Cao W, Lan XL (2005) Uptakekinetics of 99mTc-MAG3-antisense oligonucleotideto PCNA and effect on gene expression in vascularsmooth muscle cells. J Nucl Med 46:1052-1058
86. Qin G, Zhang Y, Cao W et al (2005) Molecular imaging of atherosclerotic plaques with technetium-99m-labelled antisense oligonucleotides. Eur J Nucl MedMol Imaging 32:6-14
87. Dewanjee MK, Ghafouripour AK, Kapadvanjwala Met al (1994) Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med35:1054-1063
88. Suzuki T, Wu D, Schlachetzki F et al (2004) Imagingendogenous gene expression in brain cancer in vivowith 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology.J Nucl Med 42:1766-1775
89. de Varies EF, Vroegh J, Dijkstra G et al (2004)Synthesis and evaluation of a fluorine-18 labeled antisense oligonucleotide as a potential PET tracer foriNOS mRNA expression. Nucl Med Biol 31:605-612
90. Gambhir SS, Barrio JR, Herschman HR et al (1996)Imaging gene expression: principles and assays. JNucl Cardiol 6:219-233
91. Min JJ, Iyer M, Gamghir SS (2003) Comparison of18FFHBG and 14C-FIAU for imaging of HSV1-tkreceptor expression: adenoviral infection vs stabletransfection. Eur J Nucl Med 30:1547-1560
92. Tjuvajev JG, Finn R, Watanabe K et al (1996)Noninvasive imaging of herpes virus thymidinekinase gene transfer and expression: a potentialmethod for monitoring clinical gene therapy. CancerRes 56:4087-4095
93. Tjuvajev JG, Doubrovin M, Akhurst T et al (2002)Comparison of radiolabeled nucleoside probes (FIAU,FHBG, FHPG) for PET imaging of HSV1-tk geneexpression. J Nucl Med 43:1072-1083
94. MacLaren DC, Gambhir SS, Satyamurthy N et al(1999) Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in Living animals.Gene Ther 6:758-791
95. Kung HF, Sangren P, Kung M-P et al (1988) In vitroand in vivo evaluation of 123I-IBZM; a potential CNSD-2 dopamine receptor imaging agent. J Nucl Med30:88-94